By Brandon Lim
March 20, 2026 · 3 min readA weed called sickleweed killed more than 90% of breast cancer cells in lab dishes, Iranian researchers reported in PLOS One on February 27, 2026, though the extract remains years from a patient trial.
The finding matters less for the weed itself than for how the team found it: a computer search through thousands of plants, a method that could shorten the long hunt for drugs hidden in nature.
Sickleweed, known to botanists as Falcaria vulgaris, had never drawn serious attention as a cancer fighter before the study.
Researchers at Hakim Sabzevari University and Sabzevar University of Medical Sciences in Iran soaked the plant's above-ground parts in a water-alcohol mix and dripped the extract onto two breast cancer cell lines, MCF-7 and 4T1.
At a dose of 10 milligrams per milliliter, the extract destroyed 90.51% of the MCF-7 cells and 97.4% of the 4T1 cells within 24 hours.
Half the cells died at roughly 5.3 to 6 milligrams per milliliter, a concentration measured in milligrams rather than the far smaller amounts a purified compound would contain.
Chemical analysis turned up 22 compounds in the extract, led by a fatty acid called n-hexadecenoic acid at about 23% and the alcohol phytol at about 17%.
The cells died mostly through necrosis, a messy burst driven by reactive oxygen molecules, rather than the tidy self-destruction called apoptosis that many cancer drugs trigger.
The team never set out to study sickleweed in particular.
Instead, they built a computer network linking 3,250 plants to 667 compounds already proven to act against cancer, then ranked the plants by how many strong connections each one held.
Sixty-one plants rose to the top, and nine of them, or 14.75%, had never faced an anticancer test of any kind.
Sickleweed came off that short list, which means the lab work served to check a prediction rather than to chase a folk remedy.
The approach, called network pharmacology, fits a wider shift in how scientists hunt for drugs in nature.
A 2025 review in Current Computer Aided Drug Design noted that bringing a new drug to market can take up to 15 years and cost more than one billion dollars, pushing researchers toward computer screening before any test tube gets filled.
The same review listed eight cancer drugs already drawn from natural products, including paclitaxel, vincristine, and camptothecin.
Plants make attractive starting points because their chemicals often hit several cancer pathways at once.
A separate review published in 2025 in Natural Products and Bioprospecting put the share of anticancer drugs that trace back to plant extracts at an estimated two-thirds, with terpenes and flavonoids among the molecules that push tumor cells toward apoptosis or change which genes they switch on.
History offers one famous proof that a plant screen can end in a pharmacy.
In 1962, a botanist working for the US Department of Agriculture collected bark from a Pacific yew tree in Washington State as part of a National Cancer Institute program that gathered about 30,000 plant and animal samples between 1960 and 1981.
Chemists Monroe Wall and Mansukh Wani isolated paclitaxel from that bark in 1964, and the drug, sold as Taxol, won FDA approval for ovarian cancer in 1992 and for breast cancer in 1994.
That journey took three decades, from a strip of bark to a pharmacy shelf.
Sickleweed stands at the very start of the same road.
The Iranian team tested a crude extract, not a purified compound, and only in cells growing in plastic dishes.
The authors themselves listed the gaps: their ranking weighed network connections over chemical potency, skipped cross-validation, and still needs the extract split into single compounds.
No animal or human data exist yet, and the study makes no claim that eating or brewing the plant does anything against cancer.
The fairer headline, then, reads not new cancer drug but new place to look for one.
